Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Video

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In October 2017, ​the FDA approved axicabtagene ciloleucel (axi-cel; Yescarta) for the treatment of adult patients with certain types of large B-cell lymphoma, including DLBCL, who have not responded to or who have relapsed after 2 or more treatments. Additionally, in May 2018, another CAR T-cell therapy product, tisagenlecleucel (Kymriah) was approved in a similar indication.  

Prior to these approval​s, therapeutic options were limited for patients who relapsed after autologous stem cell transplantor were ineligible for transplant.

However, the rate of durable remission is limited to 40% to 50% ​of patients with relapsed/refractory DLBCL. As such, there is a significant need to develop additional therapies ​in this space, Hill concludes. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.